Valneva secures new debt facility, revises outlook
06/10/2025 16:58
Oct 06 (Reuters) - Specialty vaccine company Valneva VLS.PA said on Monday it has secured a new debt facility of up to $500 million, extending its debt repayment to 2030. An initial tranche of $215 million will be used to repay its existing debt, with the remaining $285 million available for future business development, it added. The company also revised its 2025 guidance. (Reporting by Jérôme Terroy; Editing by Shailesh Kuber) ((jerome.terroy@thomsonreuters.com))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency